Compare JBI & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBI | ANNX |
|---|---|---|
| Founded | 2002 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 987.0M | 812.7M |
| IPO Year | 2021 | 2020 |
| Metric | JBI | ANNX |
|---|---|---|
| Price | $5.18 | $5.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $9.17 | ★ $16.50 |
| AVG Volume (30 Days) | 1.7M | ★ 1.9M |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.36 | N/A |
| Revenue Next Year | $3.16 | $16,320.74 |
| P/E Ratio | $12.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.26 | $1.85 |
| 52 Week High | $10.80 | $7.18 |
| Indicator | JBI | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 50.48 | 44.52 |
| Support Level | $5.17 | $5.28 |
| Resistance Level | $5.66 | $5.61 |
| Average True Range (ATR) | 0.27 | 0.30 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 76.57 | 40.34 |
Janus International Group Inc is a manufacturer and supplier of turnkey solutions for self-storage, commercial, and industrial building Solutions. The company provides products that include roll-up and swing doors, hallway systems, relocatable storage MASS (Moveable Additional Storage Structures) units, and technologies for automating facility and door operation. It is operated through two geographic regions; Janus North America and Janus International. The Janus International segment is comprised of a subsidiary whose production and sales are largely in Europe and Australia. The Janus North America segment is comprised of all the other entities.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.